Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Nuria Profitos-Peleja"'
1
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target
Autor: Christopher Fegan, Christopher I. Jones, Eve Coulter, Chris Pepper, Emma Halliwell, Emma Kennedy, Barnaby Clark, Stephen Devereux, Angelo Agathanggelou, Timothy Chevassut, Thomas A Burley, Rosalynd Johnston, Tatjana Stankovic, Elisabeth Jane Walsby, Ceri E. Oldreive, Triantafillos Liloglou, Elizabeth H Phillips, Andrea Pepper, Nick Davies, Martina Seiffert, Ralph Schulz, Simon Mitchell, Nuria Profitos-Peleja
Publikováno v: Phillips, E 2021, ' TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target. ', Blood, vol. 137, no. 22, pp. 3064-3078 . https://doi.org/10.1182/blood.2020005964
BLOOD
Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor–targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db12c4b0d17f7366262ee7384d8d34c0
https://doi.org/10.1182/blood.2020005964
Zobrazit plný text záznamu
2
Abstract 5974: Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma
Autor: Nuria Profitos-Peleja, Marcelo L. Ribeiro, Adar Makovski Silverstein, Stephen Cosenza, Gaël Roué
Publikováno v: Cancer Research. 83:5974-5974
Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of B-cell lymphoma including the aggressive mantle cell lymphoma (MCL) subtype, although primary and acquired resistance is frequently observed. Interestingly, prelim
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a39673e5a5eda980f6bf5ed752f579ef
https://doi.org/10.1158/1538-7445.am2023-5974
Zobrazit plný text záznamu
3
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Autor: Miranda Fernández-Serrano, Juliana Carvalho Santos, Gaël Roué, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, Marc Armengol
Publikováno v: Cancers, Vol 13, Iss 214, p 214 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Cancers
Simple Summary Immune-based treatment strategies, which include immune checkpoint inhibition, have recently become a new frontier for the treatment of B-cell-derived lymphoma. Whereas checkpoint inhibition has given oncologists and patients hope in s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3da833e4c93c60a2b76a751cbe6d15b
https://ddd.uab.cat/record/236083
Zobrazit plný text záznamu
4
Akademický článek
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma
Autor: Mélody Caillot, Hadjer Miloudi, Antoine Taly, Nuria Profitós‐Pelejà, Juliana C. Santos, Marcelo L. Ribeiro, Elsa Maitre, Simon Saule, Gaël Roué, Fabrice Jardin, Brigitte Sola
Publikováno v: Molecular Oncology, Vol 17, Iss 12, Pp 2546-2564 (2023)
Exportin 1 (XPO1) is the main nuclear export receptor that controls the subcellular trafficking and the functions of major regulatory proteins. XPO1 is overexpressed in various cancers and small inhibitors of nuclear export (SINEs) have been develope
Externí odkaz: https://doaj.org/article/15e5148ed1e04b5480ee7573912d7a4b
Zobrazit plný text záznamu
6
Abstract 2925: Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma
Autor: Juan G. Valero, Patricia Pérez-Galán, Antonio Postigo, Clara Recasens-Zorzo, Aranzazu Chamorro-Jorganes, Marc Armengol, Francesc Bosch, Nuria Profitos-Peleja, Diana Reyes-Garau, Gaël Roué, Ray Butler, Marcelo Lima Ribeiro
Publikováno v: Cancer Research. 80:2925-2925
A significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) patients harbor a gain-of-function, heterozygous somatic mutations of the methyltransferase gene EZH2. Despite acceptable safety profile and early signs of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35180e84a99ab56a3c2b71e1f3a7e15c
https://doi.org/10.1158/1538-7445.am2020-2925
Zobrazit plný text záznamu
8
Akademický článek
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
Autor: Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana Carvalho Santos, Pedro Blecua, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin, Francesc Bosch, Manel Esteller, Emmanuel Normant, Gael Roué
Publikováno v: Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targe
Externí odkaz: https://doaj.org/article/3517b4cd1e5e41d09c3aadb61e3651bd
Zobrazit plný text záznamu
9
Akademický článek
RHOA Therapeutic Targeting in Hematological Cancers
Autor: Juliana Carvalho Santos, Núria Profitós-Pelejà, Salvador Sánchez-Vinces, Gaël Roué
Publikováno v: Cells, Vol 12, Iss 3, p 433 (2023)
Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival,
Externí odkaz: https://doaj.org/article/d4d36adea3524a08b5bd15b0cc22a948
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje